| Added by | mollevi |
|---|---|
| Group name | EquipeMY |
| Item Type | Journal Article |
| Title | Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4) |
| Creator | Robert et al. |
| Author | Marie Robert |
| Author | Marta Jarlier |
| Author | Sophie Gourgou |
| Author | Françoise Desseigne |
| Author | Marc Ychou |
| Author | Olivier Bouché |
| Author | Beata Juzyna |
| Author | Thierry Conroy |
| Author | Jaafar Bennouna |
| Abstract | OBJECTIVES: Carbohydrate antigen 19-9 (CA19-9) is a sensitive and specific serum marker in pancreatic cancer. Our retrospective analysis aims to evaluate CA19-9 decrease in patients with metastatic pancreatic cancer treated in ACCORD11/PRODIGE4 (FOLFIRINOX vs. gemcitabine). METHODS: A total of 342 patients were treated. CA19-9 was measured at 8 weeks (±2) in 160 patients from a total of 282 with abnormal CA19-9 values at baseline (gemcitabine arm, n = 75; FOLFIRINOX arm, n = 85). In the present study, 8-week CA19-9 decrease or greater CA19-9 decrease according to the 20 and 90% thresholds were analyzed. Progression-free survival (PFS) and overall survival (OS) were estimated in each subgroup. RESULTS: In the FOLFIRINOX arm, patients with an 8-week CA19-9 decrease or greater CA19-9 decrease ?20% showed improved median OS, PFS, and objective response rate. In the overall study population, median OS and PFS were significantly improved in patients with an 8-week CA19-9 decrease ?20% (vs. <20%). The 8-week CA19-9 decrease was predictive of PFS (interaction test significant according to treatment arm; p = 0.006). CONCLUSION: An 8-week CA19-9 decrease ?20% is a prognostic factor for OS and PFS. The 8-week CA19-9 decrease (20% threshold) is predictive of PFS. It could help to evaluate the efficacy of FOLFIRINOX and gemcitabine regimens. |
| Publication | Oncology |
| Volume | 93 |
| Issue | 6 |
| Pages | 367-376 |
| Date | 2017 |
| Journal Abbr | Oncology |
| Language | eng |
| DOI | 10.1159/000477850 |
| ISSN | 1423-0232 |
| Library Catalog | PubMed |
| Extra | PMID: 28982109 |
| Tags | Aged, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, CA-19-9 Antigen, CA19-9, Camptothecin, clinic, Deoxycytidine, Disease-Free Survival, Female, Fluorouracil, FOLFIRINOX, Humans, Leucovorin, Male, Metastatic pancreatic cancer, Organoplatinum Compounds, Pancreatic Neoplasms, Prognosis, Retrospective Studies |
| Date Added | 2018/11/13 - 17:25:03 |
| Date Modified | 2019/05/21 - 14:15:42 |
Institut de Recherche en Cancérologie de
